Angiodysplasia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Nikita Singh (talk | contribs) No edit summary |
Nikita Singh (talk | contribs) No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Angiodysplasia}} | {{Angiodysplasia}} | ||
{{CMG}} {{AE}} {{ | {{CMG}}; {{AE}} {{NKT}} | ||
==Angiodysplasia: cost-effectiveness of therapy== | |||
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most [[Cost-effectiveness|cost-effective]] endoscopic therapy for bleeding lesions. Pharmacological therapies are also cost-effective for patients with significant co-morbidities who cannot undergo endoscopic therapy.<ref name="pmid17024322">{{cite journal| author=Olmos JA, Marcolongo M, Pogorelsky V, Herrera L, Tobal F, Dávolos JR| title=Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia. | journal=Dis Colon Rectum | year= 2006 | volume= 49 | issue= 10 | pages= 1507-16 | pmid=17024322 | doi=10.1007/s10350-006-0684-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17024322 }} </ref><ref name="pmid24138285">{{cite journal| author=Sami SS, Al-Araji SA, Ragunath K| title=Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. | journal=Aliment Pharmacol Ther | year= 2014 | volume= 39 | issue= 1 | pages= 15-34 | pmid=24138285 | doi=10.1111/apt.12527 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24138285 }} </ref> | |||
== | |||
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for | |||
==References== | ==References== | ||
Latest revision as of 10:55, 15 October 2021
|
Angiodysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiodysplasia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Angiodysplasia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Angiodysplasia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]
Angiodysplasia: cost-effectiveness of therapy
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for bleeding lesions. Pharmacological therapies are also cost-effective for patients with significant co-morbidities who cannot undergo endoscopic therapy.[1][2]
References
- ↑ Olmos JA, Marcolongo M, Pogorelsky V, Herrera L, Tobal F, Dávolos JR (2006). "Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia". Dis Colon Rectum. 49 (10): 1507–16. doi:10.1007/s10350-006-0684-1. PMID 17024322.
- ↑ Sami SS, Al-Araji SA, Ragunath K (2014). "Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management". Aliment Pharmacol Ther. 39 (1): 15–34. doi:10.1111/apt.12527. PMID 24138285.